Clearpoint Neuro, Inc. key statistics and ratios

In fiscal 2025, Clearpoint Neuro, Inc. had return on equity of -95.6% and a net margin of -69.1%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Clearpoint Neuro, Inc.: financial ratios, annual
Fiscal year	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Net margin	−354.2%	−217.7%	−116.2%	−180.3%	−125.5%	−183.9%	−140.4%	−97.1%	−83.8%	−49.4%	−52.9%	−88.4%	−80.0%	−92.2%	−60.3%	−69.1%	−79.4%
Return on equity	—	—	—	—	—	—	—	—	−168.0%	−181.8%	−194.8%	−56.3%	−38.4%	−76.1%	−81.2%	−95.6%	−130.7%
Return on assets	—	−274.3%	−137.0%	−105.6%	−42.6%	−72.5%	−93.1%	−67.3%	−56.7%	−56.0%	−32.7%	−30.3%	−27.1%	−45.0%	−46.2%	−37.3%	−34.3%
R&D as % of revenue	212.8%	111.3%	49.1%	74.4%	91.5%	42.6%	45.7%	38.1%	31.4%	25.1%	36.5%	56.9%	53.0%	48.9%	39.5%	37.6%	36.1%
SG&A as % of revenue	176.0%	126.5%	119.2%	179.7%	223.0%	182.2%	72.9%	54.8%	58.8%	38.4%	41.1%	49.1%	46.8%	49.1%	38.2%	44.6%	43.6%

US$ thousands unless shown otherwise. Fiscal quarters.

Clearpoint Neuro, Inc.: financial ratios, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Net margin	−69.3%	−71.0%	−63.3%	−66.5%	−74.8%	−78.8%	−104.2%	−61.8%
R&D as % of revenue	42.9%	39.8%	41.6%	39.0%	31.1%	37.3%	42.6%	33.3%
SG&A as % of revenue	42.0%	48.1%	36.8%	40.5%	52.3%	41.2%	51.0%	31.8%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 7 checks passed · September 30, 2026

What it owns · $113m

Short-term assets $67mLonger-term assets $46m

What it owes, and who funded it · $113m

Short-term liabilities $10mLonger-term liabilities $76mShareholders' equity $27m

Short-term assets cover short-term liabilities $67m of assets due within a year against $10m of liabilities due within a year.
Short-term assets cover long-term liabilities $67m short-term assets against $76m of longer-dated liabilities.
More cash than debt $46m of cash against $51m of debt.
Debt below 40% of shareholders' equity Debt is 186% of equity.
Debt burden no higher than five years ago Debt to equity moved from 22% to 186% over five years.
A year's operating cash flow covers at least 20% of debt −$47m of operating cash flow against $51m of debt.
Operating profit covers interest at least five times over Operating income of −$32m against $5m of interest.

From Clearpoint Neuro, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

30 /100

Weak moat

How hard Clearpoint Neuro's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 1 / 20

Cash operating profit has been a median 2.7% of total assets over 6 years.
Pricing power 18 / 20

Gross margin has been a median 61.4%, moving by 3.6 percentage points (standard deviation) across 6 years.
Durability 10 / 20

Operating margin has been a median -72.3%; its worst year was -99.5%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 10 years, at a median -96.0% of revenue.
Discipline 0 / 20

The diluted share count rose 50.1% over five years; stock-based pay has been a median 19.0% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CLPT vs KRMD CLPT vs TLSI CLPT vs SNWV CLPT vs SENS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Clearpoint Neuro, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Clearpoint Neuro, Inc.